Application of Baricitinib in Dermatology

    March 2022 in “ Journal of inflammation research ”
    Jingya Zhang, Fei Qi, Jie Dong, Yaqi Tan, Ling Gao, Fang Liu
    Image of study
    TLDR Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
    Baricitinib, a first-generation JAK1/2 inhibitor, has been approved for treating rheumatoid arthritis but is now being explored for its potential in treating various dermatological conditions such as atopic dermatitis, psoriasis, vitiligo, and alopecia areata. Recent studies, including clinical trials and case reports from the past five years, have shown promising results, particularly in the treatment of alopecia areata. The review discusses the application, efficacy, side effects, precautions, and limitations of baricitinib in these skin diseases, with a detailed examination of its mechanism in alopecia areata, suggesting it as a new treatment option for skin conditions unresponsive to conventional drugs.
    Discuss this study in the Community →

    Research cited in this study

    12 / 12 results

    Related Community Posts Join

    6 / 19 results

      community Olumiant alternative for Alopecia Areata?

      in Treatment  1 upvotes 2 years ago
      A user with alopecia areata is considering treatment options like injections or Olumiant but is concerned about cost and whether delaying treatment will lead to permanent hair loss. They are seeking alternative treatments that are more affordable for a college student.

      community Olumiant active ingredient Baricitinib

      in Research/Science  1 upvotes 3 years ago
      The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

      community I am a dermatologist with a clinical interest in alopecia. AMA

      in Will treatment work for me? 3 years ago
      In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

    Related Research

    2 / 2 results